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Bone destruction of maxillary and mandibular bone by invasive oral squamous cell cancer (OSCC) raises
various problems in the management of patients, resulting in poor outcomes and survival. However, the
mechanism behind bone destruction by OSCC remains unclear. High-mobility group box 1 (HMGB1), a
highly conserved ubiquitous nuclear non-histone DNA-binding protein, has been demonstrated to be
secreted by aggressive cancers and regulate osteoclastogenesis, a central player during bone destruction.
We therefore reasoned that HMGB1 secreted by OSCCs contributes to bone destruction. Our results
showed that HMGB1 is produced by human cell lines of OSCC and promotes osteoclastogenesis via up-
regulation of the expression of receptor activator of nuclear factor kappa-В ligand in osteoblasts and
osteocytes, and consequently osteoclastic bone destruction in mice. Further, we found that these actions
of HMGB1 are mediated via the receptor for advanced glycation end products and toll-like receptors.
These findings suggest that HMGB1 of OSCC and its down-stream signal pathways are potential targets
for the treatment of bone destruction associated with advanced OSCC.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Advanced oral squamous cell cancer (OSCC) frequently invades
and destroys themaxilla andmandible bones, which is a prognostic
factor of poor clinical outcome [1,2]. Broad bone resection, which is
currently a first-line surgical treatment for bone destruction asso-
ciated with OSCC, often disturbs quality of life of a patient [3].
Development of mechanism-based therapeutic interventions has
been awaited. However, the pathophysiology of bone destruction
associated with OSCCs still remains poorly understood [4]. Recent
studies reported that stressed and injured cancer cells release
damage-associated molecular patterns (DAMPs), thereby initiating
an infection-independent inflammatory response [5,6]. High-
mobility group box 1 protein (HMGB1) is one of the mostui).
Inc. This is an open access article urepresentative DAMPs [7]. HMGB1 was first discovered as a
conserved non-histone DNA-binding protein in the nucleus [8],
however recent studies revealed that HMGB1 is secreted and me-
diates inflammatory and immune reactions [9]. Extracellular
HMGB1 binds and activates the receptor for advanced glycation end
products (RAGE) and toll-like receptor 4 (TLR4) and promotes the
activation of immune cells, induction of proinflammatory cyto-
kines, stimulation of cell adhesion and migration, and the promo-
tion of cell proliferation and angiogenesis [10]. Of note, HMGB1
expressionwas found to be increased in several types of tumors and
HMGB1 levels are elevated in the circulation in cancer patients [11].
Further, it is reported that HMGB1 stimulates osteoclastogenesis
via regulating the expression of the receptor activator of nuclear
factor kappa-В ligand (RANKL) [12].
To determine the molecular mechanism by which invasive
OSCCs destroy maxillary and mandibular bone, we investigated the
expression of HMGB1 in human OSCC cell lines and the effects ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Expression of HMGB1 in bone-invasive OSCC of patients, OSCC cell lines and the effects of HMGB1 antibody, TLR4 antagonist TAK-242, and RAGE antagonist FPS-ZM1 on
human OSCC cell lines. A: HMGB1 expression in human oral normal tissue (left panel) and in human bone-invasive advanced oral cancer (right panel). B: Scatterplot analysis of the
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mice. Our results provide the first evidence that OSCCs produce and
secrete HMGB1, which in turn increases the expression of RANKL in
osteoblasts and osteocytes, thereby promoting osteoclastic bone
destruction.
2. Materials and methods
2.1. Reagents
Anti-HMGB1 Chicken IgY neutralizing antibody (polyclonal
#326052233) was purchased from SHINO-TEST Corporation
(Kanagawa, Japan). RAGE antagonist FPS-ZM1 (#11909) and TLR4
antagonist TAK-242 (#13871) were purchased from Cayman
Chemical (Ann Arbor, MI). Anti-HMGB1 antibody (anti-mouse,
monoclonal, GTX628834) was purchased from Gene-Tex (Irvine,
CA). Anti-NF-kB p65 antibody (anti-rabbit, polyclonal, #ab16502)
and Anti-TLR4 antibody (anti-rabbit, polyclonal, #ab13556) were
purchased from Abcam (Cambridge, UK). Anti-RAGE antibody
(anti-mouse, monoclonal, #sc-80652) was purchased from Sant
Cruz Biotechnology (Dallas, TX). Anti-RANKL antibody (anti-rabbit,
polyclonal, #bs-0747R) was purchased from BIOSS (Woburn, MA).
Horseradish peroxidase (HRP)-conjugated IgG antibody (goat anti-
rabbit, monoclonal, #7074), HRP-conjugated IgG antibody (goat
anti-mouse, monoclonal, #7076) were purchased from Cell
Signaling Technology (Danvers, MA).
2.2. Cell culture conditions
The human OSCC cell lines SAS (#JCRB0260), HSC-2
(#JCRB0622), and HSC-3 (#JCRB0623) were obtained from the
Human Science Resources Bank (Osaka, Japan). They were cultured
in Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific,
Waltham, MA) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and 1% penicillin-streptomycin. Primary mouse
osteoblast cells (OBC12) (Cosmo Bio, Tokyo) and the mouse osteo-
cytic cell line MLO-A5 (Dr. T. Bellido, Department of Anatomy and
Cell Biology, Indiana University, IN) were cultured in a-minimal
essential medium (Thermo Fisher Scientific) containing 5% FBS. The
mouse macrophage cell line RAW264.7 was cultured in a-MEM
containing 10% FBS. All cell lines were cultured in an atmosphere of
5% CO2 at 37 C.
2.3. Immunohistochemical analysis of bone-invasive OSCC samples
We analyzed the expression of HMGB1 in bone-invasive human
OSCC tissue and adjacent normal tissue from patients treated at
Okayama University Hospital. The specimens were incubated with
anti-HMGB1 antibody (1:200) overnight. The immunoreaction was
visualized with the use of a DAB peroxidase substrate with VEC-
TASTAIN Elite ABC Kit (Vector Labs, #PK-6102, Burlingame, CA).
Quantification was performed using Image J, and the relative in-
tegrated density was calculated. The study was approved by the
Ethics Committee of Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences (#206-003).
2.4. Cell proliferation assay
SAS, HSC-2, HSC-3, RAW264.7, OBC12, and MLO-A5 cells were
cultured in six-well culture plates at 1  105 cells per well with theHMGB1-positive areas in oral normal tissues (n ¼ 16) and oral cancers (n ¼ 16). Error bars
(p < 0.0001). C: Expression of HMGB1 in human OSCC cell lines including SAS, HSC-2, and H
cells by Western analysis. E: Effects of HMGB1 neutralizing antibody, RAGE antagonist FPS
excluding trypan blue were counted. Data represent relative ratio over control. *p < 0.05.presence or absence of the HMGB1-neutralizing antibody, TAK-242
or FPS-ZM1. After 48 h, the cells were counted using a TC20 auto-
mated cell counter (Bio-Rad, Hercules, CA).
2.5. Western blot analysis
RAW264.7, OBC12, and MLO-A5 were cultured with SAS OSCC-
conditioned medium with the HMGB1-neutralizing antibody,
TAK-242 or FPS-ZM1. The cell lysate samples were electrophoresed
in 4e12% sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) gels, and the proteins were transferred onto pol-
yvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories)
and blocking with 5% skim milk. Antibodies against
HMGB1(1:1000) RANKL (1:500), RAGE (1:1000), TLR4(1:1000) NF-
kB p65 (1:1000) were used as a primary antibody. HRP-conjugated
anti-rabbit antibody (1:2000) and HRP-conjugated anti-mouse
antibody (1:2000) were used as the secondary antibody. A Chem-
iDoc MP system (Bio-Rad Laboratories) was used for the analysis of
western blots.
2.6. Osteoclast differentiation and activity assay
Bone marrow cells were obtained from the femurs and tibiae of
4-week-old male C57BL/6 mice, purchased from Charles River
Laboratories (Yokoyama, Japan). Under anesthesia with 0.4 mg/kg
of medetomidine, 4.0 mg/kg of midazolam and 5.0 mg/kg of
butorphanol, the mice were sacrificed by cervical dislocation. Cut
both femurs and tibia ends and flushed out marrow cells with
phosphate-buffered saline using 27gauge needle. The cells were
then incubated in a-MEM with 30 ng/ml M-CSF (R&D System,
Minneapolis, MN) for 24 h. Non-adherent cells were transferred to
48-well plates. The cells were supplemented with 30 ng/mL
macrophage colony stimulating factor and 10 ng/mL RANKL
(PEPROTECH, Rocky Hill, NJ) and were cultured with SAS OSCC-
conditioned medium with the HMGB1-neutralizing antibody or
TAK-242 or FPS-ZM1. Following five days of incubation, the cells
were fixed and stained for TRAP/ALP Stain Kit (FUJIFILMWako Pure
Chemical Corporation, Osaka, Japan). The number of TRAP-positive
multinucleate cells (nuclear number >3) in each well was counted.
For the osteoclast activity assay, corrected bone marrow cells
were transferred to osteo assay surface 24-well multiple well plates
(#3987, Corning, Lowell, MA). Following six days of incubation, the
cells were fixed and viewed under a fluorescence microscope (IX81,
Olympus). The area of pits on the plates was determined using
image J.
2.7. Animal experiments
All the animal experimental protocols were approved by the
Ethics Review Committee for Animal Experimentation of the
Okayama University Graduate School of Medicine and Dentistry
(approval no.OKU-2018701 and OKU-2018509).
Mouse models of bone invasion by human OSCC a was estab-
lished in 7-week-old male BALB/c nude mice (n ¼ 8 per group;
n ¼ 32 total; mean body weight, 24.0 g; Charles River Laboratories)
by the inoculation of 1  105 SAS cells into the bone marrow space
of the right tibial metaphysis under general anesthesiawith 0.4mg/
kg of medetomidine, 4.0 mg/kg of midazolam and 5.0 mg/kg of
butorphanol. At seven days after tumor cell inoculation, the mice
were divided into four groups (control, HMGB1 neutralizing: Mean ± SD. There was a significantly increased expression of HMGB1 in oral cancers
SC-3 by Western analysis D: Expression of HMGB1 receptor TLR4 and RAGE in the bone
-ZM1, and TLR4 antagonist TAK-242 on cell proliferation of OSCC cell lines. Live cells
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groups were administered intraperitoneal of 100 ml of a solution
each containing TAK-242 and FPS-ZM1 (1mg/kg) in PBS five times a
week and the control group was administered PBS alone. The
HMGB1 neutralizing antibody group was administered 100 ml so-
lution containing HMGB1 neutralizing antibody (1 mg/kg) in PBS
three times for two weeks. At the end of the experimental period
(day 21), the mice were sacrificed and the right tibias of the mice
that had been injected with the cancer cells were excised and then
fixed in 4% paraformaldehyde phosphate buffer solution.
2.8. In vivo radiography and measurement of osteolytic lesion areas
Osteolytic bone destruction was assessed on radiographs. The
bones were placed against films (22  27 cm; Fuji Industrial Film
FR: Fuji Photo Film) and exposed to soft X-rays at 35 kV for 15 s with
the use of a Sofron apparatus (Sofron). The radiolucent bone lesions
were observedmicroscopically (IX81, Olympus), and the areas were
quantified with Lumina Vision/OL (Mitani Corporation). A micro-CT
image was obtained with a SKYSCAN scanner (Bruker Japan).
2.9. Immunohistochemical analysis
The bone was decalcified and embedded in paraffin. Serial 3-
mm-thick sections were cut cross-sectionally, and the sections were
stained with IHFC stain and TRAP stain. The specimens were
incubated with RANKL (1:200) or Ki-67 (1:200) antibody, followed
by Alexa Fluor 488 anti-rabbit IgG (1:500) as secondary antibodies.
Nuclei were counterstained with Fluoroshield mounting medium
with DAPI (#ab104139; Abcam).
2.10. Statistical analyses
We analyzed the data using an unpaired Student’s t-test for
comparisons of two groups and by performing a one-way analysis
of variance (ANOVA) and post hoc Tukey’s test for the analysis of
multiple group comparisons, using Prism ver. 8.0. Results are
expressed as the mean ± standard deviation (SD). Probability (p)
values < 0.05 were considered significant.
3. Results
3.1. HMGB1 expression in human OSCC tissue
Immunohistochemical examination revealed that HMGB1
expression was increased in the bone-invasive OSCC patient’s
samples compared to the normal oral tissue (Fig. 1A). The area of
HMGB1-positive cells was increased in each OSCC sample
compared to that of the normal oral tissue (Fig. 1B).
3.2. Expression of HMGB1 and RAGE and TLR4 in the human OSCC
cell lines and bone cells
We then investigated the expressions of HMGB1, TLR4 and
RAGE, which are receptors of HMGB1, in the human OSCC cell lines
and bone cells. SAS cells strongly expressed HMGB1 compared to
the other OSCC cell lines (Fig. 1C). Of interest, pre-osteoclastic cells
(RAW264.7) expressed TLR4, whereas osteocyte-like MLO-A5 cells
expressed RAGE (Fig. 1D).
3.3. Role of HMGB1 in cell proliferation of OSCC cell lines and bone
cells
We next evaluated the role of HMGB1 in cell proliferation of
OSCC and bone cells in vitro by testing a neutralizing antibody toHMGB1 and an antagonist to RAGE, FPS-ZM1 and TLR4, TAK242.
Cell proliferation of the human OSCC cell line SAS was significantly
suppressed by the treatment with FPS-ZM1 and the HMGB1
neutralizing antibody (Fig. 1E). In contrast, neither the HMGB1
antibody nor TAK-242 and FPS-ZM1 showed the effects on cell
proliferation of HSC-2 and HSC-3 cells that produce less amounts of
HMGB1 than SAS cells. Of interest, cell proliferation of the pre-
osteoclastic RAW264.7 cells was suppressed by the treatment
with the HMGB1 antibody and TAK-241 and FPS-ZM1. However,
there were little effects of the HMGB1 antibody and FPS-ZM1 and
TAK-242 on cell proliferation of OBC12 osteoblasts and MLO-A5
osteocyte-like cells. These results suggest that HMGB1 is an auto-
crine growth factor that stimulates cell proliferation via the binding
to RAGE in the human OSCC cell line SAS. Our results also show that
HMGB1 promotes cell proliferation of pre-osteoclasts via activation
of TLR4 signaling in a paracrine manner.
3.4. OSCC-derived HMGB1 promotes osteoclastogenesis and bone
resorption
HMGB1 was reported to promote osteoclastogenesis in rheu-
matoid arthritis [12]. Therefore, we determined the effects of
cancer-derived HMGB1 on osteoclastogenesis in bone marrow
cultures and bone resorption in pit assay. We cultured mouse bone
marrow cells with suboptimal dose of RANKL (10 ng/ml) andM-CSF
(30 ng/ml) in the presence or absence of the conditioned medium
(CM, 30% v/v) harvested from SAS cultures, the HMGB1 antibody
(100 ng/mL), RAGE antagonist, FPS-ZM1 (25 nM), and TLR4 antag-
onist, TAK-242 (25 nM) for 5 days. SAS CM significantly increased
the formation of TRAP-positive multinucleated osteoclast-like cells
(Fig. 2A and B) and resorption pits (Fig. 2C and D). Addition of the
HMGB1 antibody, TAK-242, or FPS-ZM1 significantly decreased SAS
CM-increased formation of TRAP-positive multinucleated osteo-
clasts (Fig. 2A and B) and pits (Fig. 2C and D). These results suggest
that SAS-secreted HMGB1 promotes osteoclastogenesis and bone
resorption through activation of TLR4 and RAGE signal pathways
expressed in osteoclasts.
3.5. Cancer-derived HMGB1 regulates RANKL expression in
osteoblasts and osteocytes
To determine the mechanism of increased osteoclastogenesis
and bone resorption by SAS-secreted HMGB1, the effects of SAS CM
on the expression of NF-kB and RANKL in osteoblasts and osteo-
cytes with or without the HMGB1 antibody, FPS-ZM1, or TAK-242
were investigated by Western analysis. SAS CM increased RANKL
expression in the mouse primary osteoblasts OBC12 and mouse
osteocyte-like cell MLO-A5, while NF-kB expression in pre-
osteoclastic RAW264.7 was not changed (Fig. 2E). HMGB1 anti-
body and FPS-ZM1 significantly reduced those effects of SAS CM.
These results suggest that cancer-secreted HMGB1 promotes
osteoclast differentiation and bone resorption via increasing RANKL
expression in osteoblasts and osteocytes.
3.6. Blocking the HMGB1 signal axis suppressed bone destruction
associated with SAS colonization in bone in the mouse model of
OSCC bone invasion
We next examined the role of cancer-secreted HMGB1 in bone
destruction associated with OSCC colonization in bone by inocu-
lation of SAS cells into the bonemarrow cavity of tibiae of mice. Soft
X-ray and micro-CT examination demonstrated that intratibial
inoculation of SAS cells developed discernible osteolytic lesions
three weeks after the inoculation (Fig. 3A and B). Importantly,
treatment with the HMGB1 antibody, TAK-242, or FPS-ZM1
Fig. 2. Effects of OSCC-secreted HMGB1 on osteoclastogenesis and bone resorption. A: Bone marrow cells were cultured with RANKL (10 ng/ml), M-CSF (30 ng/ml) with or
without SAS CM (30%, v/v), HMGB1-neutralizing antibody, TAK-242 or FPS-ZM1 HMGB1 in 48-well plates for 6 days. B: Number of TRAP-positive multinucleated osteoclast-like cells
(nuclear number >3e5) were counted (y-axis). C: Bone resorption by osteoclasts differentiated from bone marrow cells was evaluated in pit assay. D: Pit area was determined using
Image J. *p < 0.05; **p < 0.01 between the indicated groups. E: Effects of HMGB1 antibody, FPS-ZM1 and TAK-242 on the expression of the osteoclast differentiation marker NF-kB in
the RAW264.7 pre-osteoclast cell line, and the expression of RANKL in the OBC12 primary osteoblasts and the MLO-A5 osteocytic cells by Western analysis.
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Fig. 3. Effects of the HMGB1 antibody, RAGE antagonist FPS-ZM1, and TLR4 antagonist TAK-242 on SAS-associated osteolysis in tibiae in mice. Representative image of micro-
CT (A) and radiographs (B) of tibia injected with SAS cells at three weeks. C: Osteolytic lesion area in tibia from a mouse. Data are mean ± SD, n ¼ 5/group.
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tibiae of mice (Fig. 3AeC) compared to those of untreated SAS-
inoculated mice. These results suggest that cancer-secreted
HMGB1 develops bone destruction associated with OSCC invasion
in bone via propagation of HMGB1 through RAGE and TLR4.
Immunohistochemical (IHC) analysis of tibiae injected with SAS
cells demonstrated increased RANKL expression in bone colonized
by SAS cells (Fig. 4A and B). Consistent with in vitro results, RANKL
expression in osteocytes and osteoblasts was decreased by the
treatment with HMGB1 antibody, TAK-242, and FPS-ZM1. Further,intratibial inoculation of SAS cells also increased the number of
TRAP-positive multinucleated osteoclasts at the tumor-bone
interface (Fig. 4C and D), and HMGB1 antibody and FPS-ZM1
significantly decreased the number of TRAP-positive multinucle-
ated osteoclasts. Interestingly, expression of the tumor prolifera-
tion marker Ki67 was increased in SAS tumors, which was
decreased by the treatment with the HMGB1 antibody, or FPS-ZM1
(Fig. 4E and F). These results suggest that HMGB1 plays a critical
role in bone destruction associated with oral cancer and growth of
oral cancer in bone.
Fig. 4. Expression of RANKL (A and B), TRAP (C and D), and Ki67 (E and F) in SAS tumor colonizing bone by histological, histomorphometrical, and immunohistological analysis.
n ¼ 8/group.
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A role for HMGB1 in malignant tumors has been described [13],
but the involvement of HMGB1 in the bone destruction induced by
OSCC is not well understood. Our present experiments revealed the
inhibition of HMGB1 signaling inhibited the bone destruction
associated with OSCC by suppressing osteoclast differentiation and
function.
HMGB1 is a 25-kDa DNA binding protein that is generally
distributed in the nucleus [14]. The most extensively studied roles
of HMGB1 are those in the immune system. Nuclear HMGB1 acts as
a DNA chaperone that regulates DNA repair and transcription [15].
HMGB1 is also known as damage-associated molecular pattern
(DAMPs), released from dead cells and dendritic cells [16]. It has
been reported that both the level of HMGB1 secreted from various
types of cancer cells and the blood serumHMGB1 concentration are
correlated with poor prognosis [17,18]. However, the direct effects
of HMGB1 on cancer cells have not been established [19]. Our
present findings demonstrated that OSCC cells and an OSCC pa-
tient’s tissue strongly express HMGB1 and subsequently release
HMGB1 to the extracellular space. Our data indicate that SAS cells
expressed HMGB1 receptor RAGE and TLR4. In addition, the
HMGB1 blocking agent decreased the proliferation of the OSCC cell
lines in the in vitro experiment. These data suggest that autocrine
HMGB1 promotes cancer cell proliferation in OSCC.
HMGB1 is known as an inflammation cytokine. Several reports
indicated that lipopolysaccharides (LPS) and other inflammation
cytokines enhance osteoclastogenesis [20,21]. HMGB1 and other
DAMPs are considered osteoclast differentiation factors [12], but
the role of HMGB1 in bone destruction induced by OSCC remains
unknown.
As expected, our present results indicated that conditioned
medium from HMGB1-rich OSCC SAS cells increased the osteoclast
differentiation from total bonemarrow cells and increased the bone
resorption activity. Further, the HMGB1 neutralizing antibody and
the HMGB1 receptor antagonist suppressed the osteoclastogenesis
and bone resorption activity. With these results, we evaluated the
direct effect of cancer-derived HMGB1 on osteoclast differentiation
from macrophages via nuclear factor-kappa B (NF-kB) signaling,
which involves canonical and non-canonical Wnt pathways that
are essential for osteoclastogenesis [22]. Some reports indicated
that HMGB1 directly promotes maturation of osteoclasts inde-
pendent of RANKL signaling [12]. However, contrary to our expec-
tation the SAS-derived HMGB1 did not affect the expression of NF-
kB in the pre-osteoclast cell line RAW264.7.
We also observed that cancer-derived HMGB1 increased the
expression of RANKL in osteoblasts, which control osteoclast acti-
vation and differentiation. The RANKL expression in osteocytes was
proposed to be more important for osteoclastogenesis than that in
osteoblasts [23]. Surprisingly, our present findings demonstrated
that the expression of RANKL in not only osteoblasts but also in
osteocytes was increased by SAS-derived HMGB1. The RANKL
expression in both types of cells was decreased by the treatment
with neutralizing antibody and the RAGE antagonist but not the
TLR4 antagonist. It was reported that advanced glycation end-
products that are ligands of RAGE are essential for RANKL in oste-
oblasts [24]. Our present results indicate that the HMGB1 signaling
promote RANKL expression in osteoblasts and osteocytes.
In light of our in vitro data, we expected that blocking HMGB1
signaling would suppress the cancer bone destruction by OSCC SAS
cells injected into mouse tibial bone marrow. As expected, the
HMGB1 antibody, RAGE antagonist, and TLR4 antagonist signifi-
cantly decreased the bone destruction and tumor burden in the
bone marrow. The number of TRAP-positive multi-nuclear osteo-
clast cells was significantly decreased in the tibia treated with theHMGB1 antibody, RAGE antagonist, or TLR4 antagonist. Together
our data indicate that HMGB1 has a dual effect on the tumor burden
in bone: one is a direct effect on tumor progression via HMGB1
autocrine signaling, and the other is an indirect effect of osteo-
clastogenesis by RANKL regulation in osteoblasts and osteocytes.
Clinically, patients with bone-invasive metastatic malignant
tumors, breast cancer, or pancreatic cancer frequently exhibit
resistance to cytotoxic chemotherapy such as cisplatin or doxoru-
bicin. Our present findings indicate that anti-HMGB1 agents have
not only a direct tumor suppression effect but also a tumor-
independent anti-bone destruction effect. Bisphosphonate and
other bone-modifying agents have improved the prognosis of pa-
tients with bone cancer, but side effects such as medication-related
osteonecrosis of the jaw (MRONJ) [25] and atypical femoral fracture
(AFF) [26] have become a problem. The results described herein
demonstrate that anti-HMGB1 agents could become alternative
therapeutic drugs against the development of MRONJ or AFF in
patients who have been treated with standard bone-modifying
agents for bone cancer.
In conclusion, our results suggest that HMGB1 secreted from
OSCC promotes tumor growth in an autocrine manner and osteo-
clast formation and bone destruction by up-regulation of RANKL
expression in osteocytes and osteoblasts in a paracrine manner
through activation of RAGE and TLR4 signaling. Thus, blockade of
HMGB1 and its downstream signal pathways including RAGE and
TLR4 may be a mechanism-based anti-tumor approach for the
treatment of advanced invasive oral cancers.
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